On July 14, after the market closed, China Life Insurance Company Limited (SHSE: 601628) delivered a performance report that commanded significant market attention. The company anticipates its net profit attributable to shareholders for the first half of 2026 to reach between 128.933 billion yuan and 137.119 billion yuan, representing a staggering year-on-year increase of 215% to 235%.
Calculations based on the announcement reveal that in the first quarter of 2026, the company's net profit attributable to shareholders was only 19.505 billion yuan, a decline of 32.28% year-on-year, which had initially raised market concerns about its investment capabilities. However, just three months later, the net profit for the second quarter alone surged to between 109.428 billion yuan and 117.614 billion yuan, marking a quarter-on-quarter increase of 461% to 502%.
High-Beta Equity Holdings Fuel Record Interim Results
The significance of this profit surge can be understood from two perspectives. First, the second-quarter net profit alone exceeded the 83.947 billion yuan reported by Industrial and Commercial Bank of China for the second quarter of 2025. Second, this figure has already surpassed the combined net profit from the first halves of 2023, 2024, and 2025 for China Life (approximately 95.4 billion yuan). With an average daily profit exceeding 1.2 billion yuan, this sets a new record for single-quarter profitability among listed insurers.
The company attributed the strong performance to the "continuous deepening of asset-liability linkage, optimization of asset allocation, and steady progress in strategic layouts including areas related to new quality productive forces, resulting in favorable investment returns." This is not merely generic corporate language; it is supported by solid investment logic.
In the first half of 2026, the A-share market exhibited a highly polarized, sector-specific performance within a broader context of volatile upward movement. The STAR Market and sectors related to "new quality productive forces" remained particularly active, delivering substantial capital gains for institutions that had positioned themselves early.
China Life Insurance effectively caught the tail end of a "tech bull" rally in the second quarter. As of the end of Q1 2026, China Life's investment products were among the top ten circulating shareholders in 263 listed companies. In terms of sector preference, electronics and electrical equipment were the two most heavily invested industries, together accounting for over 20% of holdings. This was followed by basic chemicals, machinery and equipment, and other manufacturing-related sectors, indicating an overall portfolio bias towards hard technology and the real economy.
The company's Vice President and Board Secretary, Liu Hui, had previously outlined a clear equity investment roadmap focusing on three key directions: AI and semiconductors, healthcare and biopharmaceuticals, and green energy and new infrastructure.
Consequently, a significant portion of China Life's estimated 130 billion yuan profit likely originated from technology stocks.
More crucially, the effect was amplified by accounting classifications. Under the new financial instrument standard (IFRS 9), equity assets can be classified as either Fair Value Through Profit or Loss (FVTPL) or Fair Value Through Other Comprehensive Income (FVOCI). Gains and losses from the former directly impact the income statement, while the latter only affects net asset value. China Life has classified the vast majority of its stock holdings under FVTPL.
At the end of 2025, among the five major listed insurers in China, the proportion of stock investments designated as FVOCI assets was as follows: New China Life Insurance (18.6%), China Life Insurance (27.8%), China Pacific Insurance (37.0%), PICC Group (42.4%), and Ping An Insurance (56.5%).
China Life's FVOCI ratio is relatively low among these five major insurers. This means fluctuations in the market value of its stock portfolio are more directly and immediately reflected in its quarterly profits. When the market rises, its profit leverage is greatest; when the market falls, its profit pressure is also the most severe. This is a double-edged sword, but during the equity bull market of H1 2026, it acted as a "super amplifier" for profits.
While the investment side was the direct driver of this earnings explosion, improvements on the liability side should not be overlooked. In Q1 2026, China Life's new business value grew by 75.5% year-on-year, far exceeding market expectations. Analysts estimate that the company's new business value growth for H1 2026 will reach 42.1%, leading among listed insurers.
This sustained improvement on the liability side lays a solid foundation for future profit generation. Unlike the cyclical volatility of investment returns, growth in new business value is more sustainable and serves as a core driver of long-term value for insurance companies.
Record Profits Mask Potential Reversal Risks
Just as China Life is reaping massive profits, the technology stocks themselves are undergoing a severe valuation correction.
The trigger was news that Meta was considering selling excess AI computing capacity, sparking global concerns about an "AI compute glut." The announcement by QTS, a Blackstone portfolio company, to terminate a multi-billion-dollar data center campus project in Virginia was seen as a retreat by a major private equity player from overheated AI infrastructure investments. Combined with a sharp deleveraging event in the South Korean stock market, panic sentiment rippled into the A-share market.
As of July 13, the STAR 50 Index had fallen approximately 11.18% since the beginning of July. Among core AI and tech stocks that had doubled in value earlier this year, over 70% have seen their latest closing prices retreat more than 20% from their year-to-date highs. Memory chip stocks like Gigadevice and Biwin Storage have seen pullbacks exceeding 30%, while fiber optic communication stock Hengtong Optic-Electric has dropped over 35% in the same period.
This sudden cooling in the tech sector directly targets the core vulnerability exposed by China Life's stellar performance.
The essence of China Life's earnings surge is a successful, albeit potentially temporary, bet on the technology sector. The active performance of the STAR Market and related "new quality productive forces" sectors in Q2 led to a significant recovery in the fair value of the company's equity assets. The critical question now is whether the paper profits earned in Q2 could be reversed in Q3, given the sharp decline in tech stocks since July.
This record-setting interim report has fully demonstrated the power of the "equity amplifier" to the market: when the favored sector is performing well, the earnings leverage from equity assets can instantly boost overall company profits, creating a doubling or tripling of performance. Yet, this very report also exposes a somewhat awkward reality: the profits of an insurance company are becoming less and less like traditional insurance profits.
It increasingly resembles a public fund heavily concentrated in tech stocks, where net asset value soars in a good market and faces pressure in a down market. Under the magnifying glass of accounting standards, the volatility of the income statement has shifted from an annual cycle to a quarterly, or even monthly, cycle of billion-yuan rollercoaster rides.
One analyst team's assessment is quite precise: with their increasing market participation ratios, leading listed insurers exhibit the investment performance elasticity of "shadow stocks" for the tech innovation sector. In a sense, China Life is playing the role of a "giant tech innovation ETF."
China Life bet correctly on the first half. However, the whistle for the second half has blown, with tech stocks undergoing a painful valuation digestion phase. Whether this trillion-yuan insurance giant can continue its winning streak in the "shadow tech stock" game remains to be seen over time.
Of course, from a long-term perspective, the underlying logic of investing in China's technology industry and betting on the upgrade to new quality productive forces is sound. The strategy for insurers to leverage their long-term capital advantages to allocate to tech innovation assets and share in the dividends of industrial upgrading is also reasonable. However, the short-term volatility in the tech sector and the resulting earnings uncertainty mean investors must be psychologically prepared for a rollercoaster ride.
Comments